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REIMPORTATION FROM CANADA AND BEYOND
ANDY TROSZOK, R.PH.*
ABSTRACT
Importation of drugs from Canada is safe, as long as there is a
strict and strong regulatory structure. Canada has such a structure.
Importation through the use of mail order pharmacies is appropriate,
safe, and can provide at least a partial solution to the U.S. problem of
high cost medicines. There are no absolutely safe alternatives, but de-
cisions must be made upon the evidence. At the current time, there is
no evidence that drugs from legitimate Canadian pharmacies and, in
addition, from parallel importation from the European Union are prob-
lematic. Ultimately, those who criticize Canadian drug importation
are fear mongering and not relying upon evidence, or else they have a
vested interest. If we are going to consider importation, we need to
consider what regulations are available in the countries that are going
to import, how to make them stronger if necessary, the reality of safe
drugs coming from those countries, and the people who need the
drugs. A system that works is the Canadian system and mail order
pharmacies. We need to have the regulators, the pharmacies, and the
patients together to discuss this, so that everyone gets the benefits of
the availability and the use of appropriate medications.
INTRODUCTION
Thank you for the opportunity to speak before you. I have spoken
at many conferences on the topic of importation, and they tend to be
very one-sided. It is a pleasure to speak at a conference with a bal-
anced forum, where we can generate debate and discussion. When I
was asked to speak at this conference, I asked myself what should I
speak about? There are a lot of very reputable people here. I was told
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to speak on safety and on the appropriateness of reimportation. As
we've seen today, maybe it's better to be called importation. But
there is this area of safety. So let's jump into this issue.
SAFETY AND IMPORTATION
Is reimportation/importation safe? Yes and no. This is the an-
swer: I think if anybody says reimportation is safe, they are irrespon-
sible. At the same time, I think if people say it is not safe, they either
have a vested interest, or again, I think they are very irresponsible.
It's very easy to look at the e-mails we get on a regular basis: ads
for Viagra, ads for OxyContin, and say "reimportation is not safe."
But it's also very difficult to look at a patient who is choosing be-
tween eating food and taking a prescription medication, and say, "oh,
reimportation is bad."
With regard to our operations in Canada, I think it is important to
make certain clarifications about what we are doing because it is very
easy to criticize organizations that do not function properly. We are
not really dealing with an Internet pharmacy. This has been a frustra-
tion for the past four years that I have had to address. I am a regis-
tered pharmacist. I have never practiced Internet pharmacy. I'm not
even sure if Internet pharmacy is a practice. To me it's illegal, unpro-
fessional, unethical, and puts patients at risk.
What we are is an international mail order pharmacy. I own one
of these pharmacies. What do I utilize the Internet for? I utilize the
Internet for information, for education, to post my prices, and for pa-
tients to register with my pharmacy by filling out a form. That's all
they can do. We're not talking about third-world countries. We're
talking about Canada and some other countries that may qualify.
I testified in front of the U.S. Congress, and I specifically testified
on the issue of reimportation of medications from Canada. The hear-
ing was chaired by Dan Burton from Indiana. At the time, William
Hubbard of the FDA was testifying. Dan Burton asked him, "Do you
have evidence of counterfeiting from Canada?"
"Yes."
He stood up. He held a package of medication and it was in pow-
der form, mislabeled. He went into a fifteen-minute explanation of
how the FDA had obtained this package of counterfeit drugs.
Again, he was asked, "Where did this drug come from?"
He stated, "Thailand."
It is very convenient for organizations that oppose importation to
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utilize examples. Organizations such as the Illinois Pharmacists As-
sociation fear mongers what credible, legitimate pharmacies are doing
and tries to associate them with illegitimate organizations. The FDA
does it. The pharmaceutical industry does it. But I think that is very
irresponsible. We are not talking about criminal organizations. We're
talking about licensed, legitimate pharmacies, licensed in Canada or
licensed within the European Union, for example.
Now, do organizations, Internet pharmacies, illegitimate organiza-
tions from third-world countries exist? Absolutely they do. And I,
probably more than anybody in this room, want to make sure they are
put out of business because they make me look bad, and I am proud of
what I do. But let me give you a bit of information about the mail or-
der industry in Canada.
Reimportation has occurred for decades. As soon as there was a
price discrepancy between the two countries, we started to see people
driving across the border. It tended to be individuals. Then, in the
1990s, we actually saw bus tours from Illinois, from Minnesota, from
Maine, heading up north. There was a bit of politics around these
trips, but no real issue. The pharmaceutical companies didn't stand up
and say "drugs aren't safe from Canada." The FDA did not say drugs
were unsafe from Canada and from all of these organizations. Neither
Canada nor the United States, including the Canadian Medical Asso-
ciation and the Canadian Pharmacists Association, said this was a bad
thing. They did not object until we introduced mail order pharmacy
from Canada. We were able to reach a much broader group, and the
economics started to become a real factor. Then, reimportation be-
came an issue.
So, what is the current situation right now? Unfortunately, my in-
formation is somewhat dated. However, annually, we are probably
reaching about 1.5 to 2.0 million Americans.
SAFETY IN CANADA
What I also think is irresponsible is to fear monger and to put sce-
narios into place without evidence. At the end of the day, if we are
scientists, if we are professionals, we should make our statements and
our judgments based on evidence. And to date, there is no evidence of
any safety issue from a licensed, legitimate Canadian pharmacy. Are
there counterfeit pharmacies or Internet pharmacies somewhere in
Canada? There probably are. And if there aren't today, there will be,
because we saw what the incentives are for criminal organizations to
20051
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get into this business. But again, when we're dealing with licensed,
legitimate Canadian pharmacies, there is no evidence of problems.
There's no evidence of counterfeiting. Again, you can create fear of
counterfeiting or of transshipping; "Al Qaeda's going to transship
mass amounts of medication through Canada." But where is the evi-
dence? Ask the FDA themselves. Are there any cases of counterfeit-
ing and transshipping out of Canada through licensed legitimate
pharmacies? The answer is no. And it's too bad that Health Canada
is not here, because Health Canada should be here. It's a disgrace that
we are challenged globally about our standards, and no one in Health
Canada is willing to stand up and talk about that.
WHO ARE THE CUSTOMERS?
Who is ordering these drugs from Canada? Well again, we saw
statistics. What was it-fifty or sixty million uninsured? There are
other statistics. Maybe there are 100 million underinsured. I deal
with these patients. These are elderly patients on fixed incomes, and
they cannot afford their medication. Now another thing that we do,
and again this goes back to regulations and being professionals, we
only deal in chronic, life-saving medications. My pharmacy does not
sell Viagra, even though I would make a lot more money selling Via-
gra. I do not ship insulin. We do not ship narcotics because that
would be completely illegal. Not "somewhat illegal," which I guess is
what I am doing. I always wonder if I am ever going to be handcuffed
at the border.
What kind of states and municipalities are ordering drugs from
Canada? Currently, we have about five states that have active pro-
grams. I would say I am contacted about once a month from a state
wanting to look at our activities. i was involved with Illinois. I was
involved with Minnesota, very closely with Governor Pawlenty's of-
fice, to help set up their program. I think both programs are doing
quite well and have very good guidelines. There are four cities doing
it. Springfield, Massachusetts is one that has been in the news and ac-
tually showing major savings. Now I am not sure if these types of or-
ganizations should be ordering, but they are; and they are growing,
probably weekly.
What about other organizations? Who else is ordering? There is
the National Association of the Terminally Ill. This organization is
very interesting because you have to look at who is addressing the is-
sue of pricing. I will give credit to the Illinois Pharmacists Associa-
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tion who has gone out and looked at how we can get patients the best,
cheapest medications possible. Utilize the pharmaceutical card pro-
grams. Utilize generics. But in that whole mix, Canadian reimporta-
tion can be part of that mix. Ironically, the National Association of
the Terminally Ill does that exactly. They take a patient and they say,
where can we get your medications the cheapest way possible? They
utilize all those resources that the Illinois Pharmacists Association
does, plus they look at reimportation. If none of the former work, and
in many cases they do not, then they utilize Canadian reimportation.
SAFETY REFRAIN
Hopefully, I am not going to beat this issue to death, but let us
consider safety once again. I look at three parameters: quality control,
regulation, and trained staff. As was mentioned, Health Canada is the
department responsible for drug management in Canada, and Canada
does have one of the most advanced and safest drug approval systems
in the world. The FDA would like you to think that they know noth-
ing about Canada and nothing about Health Canada. Again, these
were the statements that William Hubbard made to Congress, includ-
ing that the FDA had no jurisdiction and had no information, even
though we are the U.S.'s largest trading partner. The FDA would like
you to think, and would like U.S. citizens to think, that it knows noth-
ing about Canada. But that is completely wrong. There are common
agency mandates. There are coordinated efforts between the two or-
ganizations, in terms of research, in terms of drug approval, in terms
of actual counterfeits. These organizations work hand-in-hand.
What is actually more important from a Canadian perspective is
how the Canadian agencies involved in drug distribution are licensed.
This is similar to the United States. Federally, we license drug ap-
proval. The wholesale market in Canada is a very closed system.
How do I know? Because I actually own a wholesale business, and to
get a wholesale license in Canada is very difficult. There are applica-
tion processes including inspections, criminal checks, and ongoing in-
spections. And correct me if I'm wrong, and there's a wholesaler in
the room, my understanding is that in the United States, all it takes is a
driver's license and $1000. I could be wrong. I apologize if I am.
But, that is why cases of counterfeiting have been almost a non-issue
in Canada.
Provincially, just like in the United States, pharmacy and pharma-
cists are managed and regulated at the provincial level, as they would
20051
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be at the state level. So, in terms of safety, we have great regulation.
One thing that we did touch on, manufacturing is starting to become
centralized. Why is it starting to become centralized? Because the
pharmaceutical industry realized that if we centralize things, we pay
less.
Now we are not dealing with FDA-approved drugs. The argu-
ment is that the drugs we are dealing with in Canada, and let us say in
the United Kingdom, are equivalent because they are manufactured in
one facility. Is that to say that there's a conveyer belt that runs for the
United States, and there is a conveyer belt that runs for the rest of the
world? No. It wouldn't make any cost sense to do so, and it does not
happen that way.
Let us look at what actually is out there. Congress commissioned
a research report in May 2003. Experts went to Canada and met with
Health Canada. They did massive inspections, and Canada is as safe,
if not safer, than the United States. And the "if not safer" was the
wholesale system. We've been inspected by numerous state pharmacy
boards and came up with good results.
There was a comment from the doctor this morning that there
were some issues with Canadian pharmacies. Absolutely. There are
issues with U.S. pharmacies. But we function in a regulated system
that allows us, if there are issues, to correct them; if you do not correct
them, you are not going to get accredited. Again, we work in a system
that works.
There was also discussion about the current Congressional bills on
importation. But again, I go back to the evidence. There is no re-
ported case of harm, and no case of counterfeiting or transshipping
through Canadian pharmacies.
For the health care professionals in the room, let us look at a
safety issue. And again, to the critics of importation, I know you have
criticisms or you think you have criticisms, but why don't you have
solutions? Solutions are what we really need. What are you going to
tell the little old grandma who is choosing between eating and taking
her prescription medication? What are you going to tell the couple
who are sharing drugs because they think "well, if I take half my Lipi-
tor, I'm going to get at least half the benefit." Well, that is not the
way drugs work. You and I know that.
You know I'm not here to beat up on the pharmaceutical industry;
I worked for the pharmaceutical industry, and they treated me very
well. But what I would like to be able to do is put this issue of safety
aside. If there is a safety issue, then our Canadian government better
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start making inquiries to Pfizer and Merck about sending substandard
drugs to Canada. You are not seeing a lot of dead Canadians because
they are using Canadian prescriptions. That is reality. They are the
same drugs.
PROFITS AND PRICING
Let us talk about profits because this is what it is all about. Again,
in a country that is focused on profits, I envy the capitalistic spirit in
the United States. If we consider profits, then reimportation will
negatively affect research and development. There is a notion that
Canada, and the rest of the industrial world, is getting an unfair ride.
They have unfair policies. And these poor drug manufacturers are not
making any money in Canada.
They are publicly traded companies. You can see how much
money they make, return on revenue: Pfizer; Eli Lilly; 28.4, 24.4%,
plus 18.6% profit for the pharmaceutical industry. Then you see
community pharmacies at 2.1%. I am somewhere down there unfor-
tunately. But again, this shows you that these industries are incredibly
profitable, and they will continue to be profitable. What is ironic is
that Boston University did a research study that showed reimportation
would make pharmaceutical companies actually more profitable in the
long-term.
What about research and development? I have seen numbers as
low as 12% of research and development costs relative to marketing.
I actually had the pleasure of speaking with Dr. Arnold Relman. He's
a medical doctor at Harvard, and the former editor of the New Eng-
land Journal of Medicine. He said the rhetoric is stirring, but the ar-
guments simply do not hold. First, research and development consti-
tutes a small portion of the budgets of the large drug companies,
whereas their marketing and advertising expenditures are much
greater. Furthermore, they make more in profits than they spend on
research and development. That is the reality.
Let us address the issue of unfair pricing. In Canada, if a com-
pany wants to have a monopoly on a product, they can, through a pat-
ent. Our federal government says, "Well, we will not negotiate with
you. If we are going to give you exclusivity in the market to recoup
your investment and to have the opportunity to make a profit (and they
do make extensive profits in Canada), we should actually have a say
in how you price the medications." It makes sense to me. But I am
Canadian, and we do not really make sense all that often.
2005]
7
Troszok,: Reimportation from Canada and Beyond
Published by CWSL Scholarly Commons, 2005
62 CALIFORNIA WESTERN INTERNATIONAL LAW JOURNAL [Vol. 36
Brand name manufacturers impede generic manufacturers getting
into market. The first thing that happens when a generic manufacturer
comes to market is they sue it. Why? Because they tie it up in the
courts and the amount of money they spend in courts is a fraction of
the amount of money they are going to make in the next six months to
a year.
One thing 'we do differently in Canada than in the United States
and in the European Union is that we do not allow direct-to-consumer
advertising. (It is an extended amount of spending that the consumer
has to pay for. And lobbying by the brand name companies too, that
is a lot of golf games.)
APPROPRIATENESS OF IMPORTATION
Let us look at this issue of appropriateness. Is reimportation ap-
propriate? Well, if we are only tapping two million Americans, we
are not affecting or solving the problem in the U.S. And I'll be the
first one to say that reimportation is not the ultimate solution. But you
know an immediate solution. And why do I know that? Because
every single day, I send medications to people. I am not going to sit
here and say all my clients are choosing between eating and taking
their medications, but some of them are. I know that if I were not
around, those people would not be taking their medication, which
would result in their being hospitalized and maybe dying.
We have a proven system if it is done appropriately. Again, to the
Illinois Pharmacists Association, we have an actual pharmacist-to-
pharmacist model. I have developed it myself and presented it to
three states. We are looking at implementing it with U.S. pharmacists.
U.S. pharmacists should provide the cognitive service, the care, the
one-on-one interaction. There is enough differential to pay for the
pharmacist in the U.S. and to allow the Canadian pharmacist to fill
and dispense the prescription. Create a collaboration. It can be a so-
lution. It can work. But when I showed it to the FDA, they told me
the pharmacist would be charged with aiding and abetting.
The message of our minister Ujjal Dosanjh was actually correct.
We cannot be the drugstore for the U.S. But that is why direct-to-
consumer works, because the people in need, the people that really do
not have any other options, are coming to Canada. Not all of them.
Some of them are going to Mexico and some of them, yes, are unfor-
tunately going to rogue sites, and there is a health issue. But we can
solve that issue. The problem is the agencies that I am willing to work
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with will not discuss the issues. I went to the FDA and asked, "what
do you guys want? Do you guys want to inspect my facility? Do you
want me to get extra licensing?" They basically said we do not even
want to talk to you. We did this for political relations.
There was mention of VIPPS, VIPPS certification. I applied for
VIPPS certification. I could be certified as a VIPPS pharmacy if I had
a pharmacy in the U.S. I could be VIPPS-certified if I had a Canadian
pharmacy that only sold to Canadians. But as soon as I sell to Ameri-
cans, I cannot be VIPPS-certified. It is complete hypocrisy.
REIMPORTATION BEYOND BORDERS
I think we have an ability to go beyond the borders, but the coun-
tries selected have to have comparable safety, quality, and regulatory
parameters to Canada. Otherwise, there is no point in going. I think
patients need to be part of the process. For example, my pharmacy, if
you come to my mail order pharmacy with a legitimate prescription,
you have the choice of having your prescription filled in Canada or in
the United Kingdom. These are the only two countries where I feel
comfortable going because I have inspected the facilities in the United
Kingdom. Now again, there is fear mongering, and there are state-
ments made by Canadian pharmacists who say, "we are going else-
where." Well, go elsewhere. But if you are a Canadian pharmacy,
and there are regulatory parameters which can be implemented, pre-
venting you from sending a drug from India, then we can regulate that
kind of practice out of business.
I have also looked at parallel trade. Again, it does have its chal-
lenges. But again, if we look at the evidence, it actually does work.
There have been no cases of counterfeiting. The German commission
said that in the ten years that they have been doing parallel trade, not a
single case of counterfeiting has been encountered. We have to look
at the evidence.
CONCLUSION
Reimportation can occur if it starts safely. I am the first to say we
need stricter and stronger regulations. But we need to have the people
who control the regulations at a table discussing this. We all lose with
counterfeiting and transshipping. We all lose when patients cannot af-
ford their medications because those patients will suffer. They will
become a further burden on the social structure of a country. I think
2005]
9
Troszok,: Reimportation from Canada and Beyond
Published by CWSL Scholarly Commons, 2005
64 CALIFORNIA WESTERN INTERNATIONAL LAW JOURNAL [Vol. 36
reimportation can be beneficial to pharmacists, pharmacies, pharma-
ceutical manufacturers, and governments. But most of all, I think it
can be most beneficial to patients. Thank you.
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